Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Phase 1/2 Completed 7 enrolled University of Alabama at Birmingham Eli Lilly and Company · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with positive EGFr expression.

Timeline

Start: 2001-06
Primary completion: 2002-01
Completion: 2006-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous
Background	Gemcitabine	Small molecule	—	Intravenous

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Summary

Timeline

Drugs

Indications